{"id":51853,"date":"2022-12-12T15:02:09","date_gmt":"2022-12-12T14:02:09","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/"},"modified":"2022-12-12T15:02:09","modified_gmt":"2022-12-12T14:02:09","slug":"functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/","title":{"rendered":"Functional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform"},"content":{"rendered":"
\n

\nCompany is positioned to scale predictive platform\u2019s impact <\/i>in cancer patient therapy selection and preclinical pharma services<\/i><\/b>\n<\/p>\n

GREENVILLE S.C.–(BUSINESS WIRE)–#3dcellculture<\/a>–Kiyatec Inc. announced today a closing of its Series C funding round totaling US$18 million from new and existing investors. New investor Bruker (Nasdaq: BRKR) led the financing and was joined by existing investors Seae Ventures, VentureSouth, and LabCorp (NYSE: LH). Use of funds will focus on accelerating adoption of the company\u2019s commercially available clinical testing and preclinical pharma services, which add value across the life cycle of successful cancer drugs.\n<\/p>\n

<\/a><\/p>\n

\nKiyatec is an established leader in functional precision oncology, in which clinically relevant laboratory models measure the response of living cells to cancer drugs. In this emerging field, the gold standard for performance is direct correlation between measured response in the lab and real world, patient-matched clinical outcomes. “Transforming therapy selection for cancer patients \u2013 which functional precision oncology is positioned to deliver \u2013 relies on meaningfully connecting cell death in the lab to matched cells also dying in the patient\u2019s body, i.e., to clinical response,\u201d said Kiyatec CEO Matt Gevaert, PhD. \u201cThis unlocks the potential to significantly improve cancer outcomes, a mission we\u2019re proud to be advancing.\u201d With respect to published, peer-reviewed data demonstrating such clinical correlation in solid tumors, Kiyatec\u2019s platform has industry leading performance and a clinically attractive 7-10 day turnaround.\n<\/p>\n

\nKiyatec\u2019s analytically validated 3D-Predict\u2122 Glioma test informs therapy selection in the clinic for glioblastoma (GBM) and other high grade glioma patients and is commercially available (US*). In May 2021 the company published clinical data demonstrating the test\u2019s accurate and statistically significant prediction of high-grade glioma patients\u2019 individual responses to cancer drugs; notably, to drugs they had not yet been treated with. In this cancer indication, known for its low survival, newly diagnosed patients under study lived six months longer when identified by 3D-Predict\u2122 Glioma as responders to standard of care drug therapy as compared to those identified as non-responders. Earlier this year at annual meetings of the American Society for Clinical Oncology (ASCO, June) and the Society for Neuro-Oncology (SNO, November), Kiyatec expanded its clinical evidence of continuing excellent test performance. In October, the company also announced a unique strategic partnership with NICO Corporation, a neurosurgical medical device innovator, to facilitate improved tissue quality as a success factor in prediction of tumor response to cancer chemotherapies and targeted agents.\n<\/p>\n

\nAs a complement to its clinical testing, Kiyatec\u2019s preclinical 3D cell culture services augment pharma clients\u2019 drug development by providing clinically relevant assessment of primary human drug response prior to clinical studies. With demonstrated strong clinical correlation, Kiyatec\u2019s platform addresses significant limitations of historic preclinical testing approaches that have lower correlation to patient outcomes. The advantages of its clinically correlated platform, and its applicability to complex immune oncology therapies, are drivers of Kiyatec\u2019s growing revenue in preclinical services. Accommodating this growth is well timed with respect to the company\u2019s recently expanded laboratory and office space as the anchor tenant of Main Street Labs in vibrant downtown Greenville, SC.\n<\/p>\n

\nAbout Kiyatec:\n<\/p>\n

\nKiyatec is a functional precision oncology company that measures the response of each patient\u2019s live cancer cells to inform oncologists\u2019 treatment selection decisions. The company\u2019s Clinical Services offers clinical testing for high-grade glioma, and is developing assays for use in ovarian, breast, non-small cell lung cancers, and rare tumors in its CLIA certified lab. The company\u2019s Drug Development Services works in partnership with leading biopharmaceutical companies to unlock response dynamics for their pre-clinical investigational drug candidates across the majority of solid tumor types. For more information, visit www.kiyatec.com<\/a> and connect with us on LinkedIn<\/a> and Twitter<\/a>.\n<\/p>\n

\n*3D Predict\u2122 Glioma is not commercially available in CA, NY or RI at this time<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMatt Gevaert, PhD
\n
Chief Executive Officer
\n
864-502-2013\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Company is positioned to scale predictive platform\u2019s impact in cancer patient therapy selection and preclinical pharma services GREENVILLE S.C.–(BUSINESS WIRE)–#3dcellculture–Kiyatec Inc. announced today a closing of its Series C funding round totaling US$18 million from new and existing investors. New investor Bruker (Nasdaq: BRKR) led the financing and was joined by existing investors Seae Ventures, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51853","6":"format-standard","7":"category-industry"},"yoast_head":"\nFunctional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Functional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Company is positioned to scale predictive platform\u2019s impact in cancer patient therapy selection and preclinical pharma services GREENVILLE S.C.–(BUSINESS WIRE)–#3dcellculture–Kiyatec Inc. announced today a closing of its Series C funding round totaling US$18 million from new and existing investors. New investor Bruker (Nasdaq: BRKR) led the financing and was joined by existing investors Seae Ventures, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-12T14:02:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221212005115\/en\/1661039\/21\/Kiyatec_transparent_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Functional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform\",\"datePublished\":\"2022-12-12T14:02:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\\\/\"},\"wordCount\":662,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221212005115\\\/en\\\/1661039\\\/21\\\/Kiyatec_transparent_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\\\/\",\"name\":\"Functional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221212005115\\\/en\\\/1661039\\\/21\\\/Kiyatec_transparent_logo.jpg\",\"datePublished\":\"2022-12-12T14:02:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221212005115\\\/en\\\/1661039\\\/21\\\/Kiyatec_transparent_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221212005115\\\/en\\\/1661039\\\/21\\\/Kiyatec_transparent_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Functional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Functional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/","og_locale":"en_US","og_type":"article","og_title":"Functional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform - Pharma Trend","og_description":"Company is positioned to scale predictive platform\u2019s impact in cancer patient therapy selection and preclinical pharma services GREENVILLE S.C.–(BUSINESS WIRE)–#3dcellculture–Kiyatec Inc. announced today a closing of its Series C funding round totaling US$18 million from new and existing investors. New investor Bruker (Nasdaq: BRKR) led the financing and was joined by existing investors Seae Ventures, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-12T14:02:09+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221212005115\/en\/1661039\/21\/Kiyatec_transparent_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Functional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform","datePublished":"2022-12-12T14:02:09+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/"},"wordCount":662,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221212005115\/en\/1661039\/21\/Kiyatec_transparent_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/","url":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/","name":"Functional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221212005115\/en\/1661039\/21\/Kiyatec_transparent_logo.jpg","datePublished":"2022-12-12T14:02:09+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221212005115\/en\/1661039\/21\/Kiyatec_transparent_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221212005115\/en\/1661039\/21\/Kiyatec_transparent_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/functional-precision-oncology-leader-kiyatec-announces-series-c-round-with-us18-million-closing-to-accelerate-adoption-of-transformational-cancer-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Functional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51853"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51853\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}